BACKGROUND: The Dieulafoy lesion is an important cause of gastrointestinal (GI) hemorrhage. Optimal treatment and long-term outcome are unknown. This study aimed to characterize the presentation of the Dieulafoy lesion and to summarize the results and report the long-term outcome of endoscopic therapy. METHODS: Data regarding diagnosis, treatment and outcomes were derived from our GI Bleed Team database, patient records and follow-up correspondence. RESULTS: Ninety Dieulafoy lesions were identified in 89 patients after a mean of 1.9 endoscopies. Their mean age was 72 years. Thirty-four percent of lesions were extragastric. Median transfusion requirement was 5 units. Two patients exsanguinated and 3 required surgery; all others were initially successfully treated endoscopically (with or without epinephrine injection): heat probe (71 patients), band ligation (3), hemoclip (1), laser (2), bipolar probe (4), sclerotherapy (2) and epinephrine alone (2). Gastric perforation occurred in 1 patient following sclerotherapy. Thirty-day mortality was 13%, 4 related to hemorrhage and 5 related to comorbidity. During median follow-up of 17 months, 34 patients (42%) died. One patient had recurrent bleeding 6 years after operation. CONCLUSIONS: Dieulafoy lesion is relatively common and often extragastric. Endoscopic therapy is safe and effective. Long-term recurrence was not evident following endoscopic ablation. Follow-up after ablative therapy appears unnecessary.
BACKGROUND: The Dieulafoy lesion is an important cause of gastrointestinal (GI) hemorrhage. Optimal treatment and long-term outcome are unknown. This study aimed to characterize the presentation of the Dieulafoy lesion and to summarize the results and report the long-term outcome of endoscopic therapy. METHODS: Data regarding diagnosis, treatment and outcomes were derived from our GI Bleed Team database, patient records and follow-up correspondence. RESULTS: Ninety Dieulafoy lesions were identified in 89 patients after a mean of 1.9 endoscopies. Their mean age was 72 years. Thirty-four percent of lesions were extragastric. Median transfusion requirement was 5 units. Two patients exsanguinated and 3 required surgery; all others were initially successfully treated endoscopically (with or without epinephrine injection): heat probe (71 patients), band ligation (3), hemoclip (1), laser (2), bipolar probe (4), sclerotherapy (2) and epinephrine alone (2). Gastric perforation occurred in 1 patient following sclerotherapy. Thirty-day mortality was 13%, 4 related to hemorrhage and 5 related to comorbidity. During median follow-up of 17 months, 34 patients (42%) died. One patient had recurrent bleeding 6 years after operation. CONCLUSIONS: Dieulafoy lesion is relatively common and often extragastric. Endoscopic therapy is safe and effective. Long-term recurrence was not evident following endoscopic ablation. Follow-up after ablative therapy appears unnecessary.
Authors: P Katsinelos; G Paroutoglou; I Pilpilidis; P Tsolkas; A Papagiannis; P Kapelidis; C Trakateli; A Iliadis; E Georgiadou; E Kamperis; S Dimiropoulos; I Vasiliadis Journal: Surg Endosc Date: 2003-06-13 Impact factor: 4.584
Authors: Luis F Lara; Jayaprakash Sreenarasimhaiah; Shou-jiang Tang; Bianca B Afonso; Don C Rockey Journal: Dig Dis Sci Date: 2010-09-17 Impact factor: 3.199
Authors: Wan Sik Lee; Sung Bum Cho; Sun Young Park; Change Hwan Park; Young Eun Joo; Hyun Soo Kim; Sung Kyu Choi; Jong Sun Rew Journal: BMC Gastroenterol Date: 2010-02-23 Impact factor: 3.067
Authors: Gustavo López-Arce; Sergio Zepeda-Gómez; Norberto C Chávez-Tapia; Sandra Garcia-Osogobio; Ada M Franco-Guzmán; Miguel A Ramirez-Luna; Félix I Téllez-Ávila Journal: Therap Adv Gastroenterol Date: 2008-09 Impact factor: 4.409
Authors: Giovanni D De Palma; Francesco Patrone; Maria Rega; Immacolata Simeoli; Stefania Masone; Giovanni Persico Journal: World J Gastroenterol Date: 2006-06-28 Impact factor: 5.742